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Abstract
Introduction: Tuberculosis remains a major public health problem worldwide. In recent years,
increasing efforts have been dedicated to assessing the health-related quality of life experienced by
people infected with tuberculosis. The objectives of this study were to better understand the
impact of tuberculosis and its treatment on people's quality of life, and to review quality of life
instruments used in current tuberculosis research.
Methods: A systematic literature search from 1981 to 2008 was performed through a number of
electronic databases as well as a manual search. Eligible studies assessed multi-dimensional quality
of life in people with tuberculosis disease or infection using standardized instruments. Results of
the included studies were summarized qualitatively.
Results: Twelve original studies met our criteria for inclusion. A wide range of quality of life
instruments were involved, and the Short-Form 36 was most commonly used. A validated
tuberculosis-specific quality of life instrument was not located. The findings showed that
tuberculosis had a substantial and encompassing impact on patients' quality of life. Overall, the anti-
tuberculosis treatment had a positive effect of improving patients' quality of life; their physical
health tended to recover more quickly than the mental well-being. However, after the patients
successfully completed treatment and were microbiologically 'cured', their quality of life remained
significantly worse than the general population.
Conclusion: Tuberculosis has substantially adverse impacts on patients' quality of life, which
persist after microbiological 'cure'. A variety of instruments were used to assess quality of life in
tuberculosis and there has been no well-established tuberculosis-specific instrument, making it
difficult to fully understand the impact of the illness.
Introduction
The assessment of patient reported outcomes (PROs) has
become more accepted and valued in the disease manage-
ment and outcome evaluation. Health-related quality of
life (HRQL) is a complex type of PRO that evaluates
health status. HRQL broadly describes how well individu-
als function in daily lives and their own perception of
well-being in physical, psychological, and social aspects
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[1,2]. Although traditional clinical and biological indica-
tors are often intrinsically related to patients' quality of
life, they fail to represent one's self-perceived function and
well-being in everyday life settings. It is known that
patients with chronic diseases place a high value on their
mental and social well-being as well as pure physical
health [3]. As a result, HRQL has become an area of
increasing interest and has been evaluated in many dis-
eases, including tuberculosis (TB). To measure HRQL, two
kinds of instruments are often used: generic and disease-
specific [1,2,4]. Generic instruments are developed to
cover the common and important aspects of health and
can be used to assess and compare HRQL across different
health conditions and sub-populations [1,4]. In contrast,
disease- or condition-specific instruments are designed to
reflect unique problems most relevant to a given disease
and/or its treatment [1,4]. Theoretically, disease-specific
instruments are more precise and more sensitive to small
but potentially important differences or changes on
HRQL, compared to generic instruments [1,4]. One spe-
cial category of generic HRQL instruments assesses "pref-
erences" for certain health states [2]. These instruments
summarize quality of life into a single utility score, reflect-
ing the 'value' people place on a health state, anchored at
0 (death) and 1 (full health). [2]. Health utility measure-
ments are often used in health economic studies.
Although effective therapy has long been available, TB
remains a major public health threat globally, with one
third of the world's population infected [5,6]. Many
aspects of TB along with its treatment could potentially
compromise patients' HRQL. For example, the standard
anti-TB therapy consists of four medications and takes at
least 6 to 9 months to complete, with serious risks of
adverse reactions [6-8]. In some communities, TB patients
are perceived as a source of infection and the resultant
social rejection and isolation leads to a long-term impair-
ment on patients' psychosocial well-being [9-14]. Many
TB patients also report to experience negative emotions,
such as anxiety and fear [13,14]. However, the current
goal of TB management is to achieve microbiological
'cure' and there has been little effort taken to consider
patients' HRQL. In 2004, Chang et. al. published a review
summarizing the English medical literature on the quality
of life in TB patients [15]. At that time, the authors were
unable to locate studies measuring HRQL using standard-
ized instruments. Over the past few years, more effort has
been dedicated to this research field. Therefore, the
present review was performed to identify published origi-
nal studies utilizing structured HRQL instruments.
Objectives
The objectives of this review were: (1) to identify HRQL
instruments used in TB research; (2) to better understand
the impact of TB disease or infection and the associated
treatment on patients' HRQL; and (3) to examine demo-
graphic, socio-economic, and clinical factors associated
with HRQL outcomes in TB patients.
Methods
Search strategies for identification of potential studies
A systematic literature search was performed using the fol-
lowing electronic databases: Medline (1950-present),
EMBASE (1980-present), Cochrane Register of Controlled
Trials (CENTRAL), CINAHL, PsycINFO, and HaPI (1985-
present). Key word searching and/or subject searching
were performed, if applicable. The following keywords
were used: tuberculosis (TB), Quality of Life (QoL), Quality
Adjusted Life Years (QALY), health utility, health status, life
quality, and well-being. The limit feature was used to select
human studies published between 1981 and 2008 written
in English or Chinese (traditional or simplified). The last
time electronic database search was conducted during July
22, 2008. The reference sections of the following key jour-
nals were manually searched for relevant articles: Interna-
tional Journal of Tuberculosis and Lung Disease, Chest,
Quality of Life Research, and Health and Quality of Life Out-
comes. Reference lists of included studies, review articles,
letters, and comments were checked afterwards. We did
not contact the authors of identified studies or relevant
experts to locate unpublished studies. Each stage of the lit-
erature searching process is illustrated in Figure 1.
Inclusion and exclusion criteria
All clinical trials and observational studies where multi-
dimensional HRQL was evaluated, either as a primary or
secondary outcome, using structured HRQL instruments
were considered in this review. Participants were those
diagnosed with active TB disease or latent TB infection
(LTBI), regardless of the site and stage of the disease and
the treatment status. There were no limitations on age,
gender, race, the origin of birth, and other socio-economic
status.
For the purpose of this review, HRQL was defined as
patients' self-evaluations of the impact of either active TB
disease or LTBI and the associated treatments on their
physical, mental, and social well-being and functioning.
The following requirements for HRQL measurement were
set a priori for studies to be included in this review: (1)
one multi-dimensional HRQL instrument or a combina-
tion of single-dimensional instruments had to be used to
capture the broad framework of HRQL; (2) the HRQL
instruments could be either generic or disease (or condi-
tion) -specific; (3) the origin of the applied instruments
had to be identifiable and traceable; (4) the HRQL instru-
ments had to have psychometric properties such as relia-
bility and validity reported from previous studies or were
assessed in the specific study being reviewed; (5) HRQL
outcomes had to be self-reported by the specific partici-Health and Quality of Life Outcomes 2009, 7:14 http://www.hqlo.com/content/7/1/14
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pant, but HRQL measurement that were completed with
help from proper proxies, such as family members and
caregivers, were also accepted.
Studies were excluded if (1) HRQL was evaluated using
qualitative methodologies, such as focus groups; or (2)
only one single dimension of HRQL (e.g., depression)
was assessed; or (3) HRQL was assessed using instruments
designed for the specific study without psychometric
properties evaluated and reported; or (4) a modified ver-
sion of a previously validated instruments (e.g., SF-36)
was used as the psychometric properties of the original
instrument could be changed by the modification.
Data extraction
If the study was included in this review, the following
information was collected: study design, inclusion and
exclusion criteria of subjects, included subjects' socio-
demographic characteristics and clinical features, HRQL
instrument(s) used, the origin and structure of HRQL
instrument(s), administration of HRQL instrument(s),
and HRQL outcomes and validation results.
Results
The literature search identified 2540 articles which were
narrowed to 26 [9-14,16-35] (Figure 1). After reviewing
the full texts, 14 studies were further excluded for various
reasons: 6 studies used qualitative methodologies [9-14];
2 studies measured only one single dimension of HRQL
[16,17]; 1 study [18] used the Short-Form 36 (SF-36) but
the response options of SF-36 were modified to 3 levels
(i.e., the same as before, better, and worse) without pro-
viding validation data; 1 study [19] used one single ques-
tion from a structured instrument; 1 study was a duplicate
and the earlier version was excluded [20,21]; 1 study [22]
used a generic instrument, the General Quality of Life
Interview (GQOLI-74), however, no relevant references
were provided to track the origin and the psychometric
properties of this instrument; 2 articles [23,24] were pub-
lished from the same study, and therefore only included
Figure 1Health and Quality of Life Outcomes 2009, 7:14 http://www.hqlo.com/content/7/1/14
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as one study for the review; another 2 articles, Marra et. al.
[25] and Guo et. al. [26], reported longitudinal and cross-
sectional results from one same study respectively, and
thus only one study was counted for the review. Therefore,
a total of 12 original studies were included in this review
[21,23,25,27-35] and an overview is presented in Addi-
tional file 1.
Of the 12 included studies, one was published in 1998
[27] and the remaining 11 were published after 2001
[21,23,25,28-35]. Nine studies were published in English
and 3 in Chinese [27,29,33]. The included studies were
carried out within different countries: 3 in China [27-29];
1 in both China and southern Thailand [33]; 2 in India
[21,35]; 2 in Turkey [30,31]; 2 in Canada [23-26]; and 2
in the USA [32,34]. Seven of the included studies were
cross-sectional [27,29-31,33-35] and 4 were prospective
cohort studies [21,23,25,28]. The remaining one study
was a randomized controlled trial (RCT) [32], but only
baseline HRQL assessment data was reported in the pub-
lished article. Among the 12 studies, three studies
included a comparison group either from the general pop-
ulation [28] or from a "healthy" non-TB sample [27,29];
one study used the normative data from the Canadian
population as the reference group [23,24]; two studies
included people with LTBI as controls [25,34]; one study
compared TB patients with a group of chronic obstructive
pulmonary disease (COPD) patients [31]; and the
remaining 5 studies did not include proper comparison
groups. Sample size (i.e., number of subjects included in
the statistical analysis) varied among the 12 studies, from
46 to 436. Only one study [23] reported how the sample
size was estimated statistically. A wide range of TB patients
were included in this review: pulmonary TB and extra-pul-
monary TB, active TB disease and LTBI, and current TB and
previously treated TB.
To measure multiple-dimensional HRQL, a variety of
instruments were involved in the included studies (Addi-
tional file 2). As a result, it was not possible to statistically
summarize the results and thus a qualitative synthesis
approach was taken for this review.
HRQL instruments used in the included studies
Nine studies included generic multi-dimensional instru-
ments with or without specific single-dimensional ones,
one study used a newly developed TB-specific multi-
dimensional instrument [21], and two studies used a bat-
tery of single-dimensional instruments [31,33].
Generic HRQL instruments
The SF-36 was used in 6 studies with different language
versions [23-28,33]. It consists of 36 items which are
aggregated into 8 subscales, including physical function-
ing (PF), role-physical (RP), bodily pain (BP), general
health (GH), vitality (VT), social functioning (SF), role-
emotional (RE), and mental health (MH) [36]. From the
8 subscales, the physical component summary (PCS) and
mental component summary (MCS) scores can be also
calculated [36]. Duyan et. al. used the 24-item Quality of
Life Questionnaire (QLQ), which covers 7 domains,
including living conditions, finances, leisure, family rela-
tions, social life, health, and access to health care [30]. The
24-item QLQ was first presented by Greenley et. al. in
1997 [37]. Finally, the long Medical Outcome Study
(MOS) core questionnaire was used in Pasipanodya et. al.
[34]. This is a generic instrument covering multiple
dimensions, including physical function, social function,
general health, vitality, and limitations due to physical
and emotional functioning [38]. The well-known SF-36
was developed and evolved based on a subset of items
from the MOS core questionnaire [38].
Specific HRQL instruments
Dhingra and Rajpal measured HRQL with the DR-12, a
new TB-specific instrument, which was developed in India
and first published in 2003 [20]. It is composed of 12
items, among which 7 cover TB symptoms (i.e., cough and
sputum, haemoptysis, fever, breathlessness, chest pain,
anorexia, and weight loss) and 5 relate to socio-psycho-
logical and exercise adaptation (i.e., emotional symp-
toms/depression, interest in work, household activities,
exercise activities, and social activities) [20,21]. All
response options are presented on 3-point scales and
equal weights are given to each item when calculating the
two domain scores and the total score [20,21]. The St.
George Respiratory Questionnaire (SGRQ) used in Pasi-
panodya et. al. [34] is a widely used specific instrument
designed for measuring HRQL in patients with chronic
obstructive pulmonary disease (COPD) and other types of
respiratory diseases. Three domain (symptom, activity,
and impacts) scores and a total score can be generated
[39]. It was developed at the St. George's Hospital Medical
School at the UK and has been translated into various lan-
guages [39].
Yang et. al. used two single-dimensional instruments, the
Chinese version Symptoms Checklist 90 (SCL-90) and
Social Support Rating Scale (SSRS) [29]. The SCL-90 is a
90-item symptom inventory designed mainly to evaluate
a broad range of psychological problems and symptoms,
including 9 dimensions: somatization, obsessive-compul-
sive behaviour, interpersonal sensitivity, depression, anx-
iety, hostility, phobic anxiety, paranoid ideation, and
psychoticism [40]. The 10-item SSRS was used to measure
the self-perceived availability and use of social support
services [27]. The study by Aydin and Ulusahin used two
single-dimensional instruments, the General Health
Questionnaire 12 (GHQ-12) and Brief Disability Ques-
tionnaire (BDQ) [31]. GHQ-12 is a short version of theHealth and Quality of Life Outcomes 2009, 7:14 http://www.hqlo.com/content/7/1/14
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GHQ-60, which was developed for screening non-psy-
chotic psychiatric disorders in the general population
[41]. The BDQ, derived from the MOS short form general
health survey, is used to measure patients' physical and
social disability level [42]. Marra et. al. [25] used the Beck
Depression Inventory (Beck-DI), along with the SF-36 and
a couple of health utility instruments. The Beck-DI is a 21-
item instrument, designed to measure the symptoms and
degree of depression [43].
In the USA study, a series of instruments or questions were
used to assess TB-infected homeless individuals' self-per-
ceived physical health, psychological profile, emotional
well-being, social support, and health care access and use
[32]. Examples included the 5-item Mental Health Index
(MHI-5) and the Center for Epidemiological Studies
Depression Scale (CES-D) [32].
Health utility instrument
Health utility, one generic measure of HRQL, reflects sub-
jective preferences for health states and also provides
quantitative estimates of HRQL under certain health states
[2]. The two studies [23-26] conducted in Canada applied
various health utility assessment techniques among TB
patients, including the Health Utility Index (HUI), Euro-
Qol (EQ-5D), Short-Form 6D (SF-6D), Visual Analogue
Scale (VAS), and Standard Gamble (SG). HUI, SF-6D, and
EQ-5D are multi-attribute health status classification sys-
tems that indirectly measure preferences for health states
[2]. SG and VAS are to directly obtain individuals' prefer-
ences using different techniques.
HUI currently consists of HUI-2 and HUI-3 [44]. HUI-2
and HUI-3 are derived from the same questionnaire but
HUI-2 has 7 domains (sensation, mobility, emotion, cog-
nition, self-care, pain, and fertility) and HUI-3 contains 8
domains (vision, hearing, speech, ambulation, dexterity,
emotion, cognition, and pain). EQ-5D consists of 5
domains, including mobility, self-care, usual activity,
pain, and anxiety/depression [2]. SF-6D is derived from a
subset of SF-36 questions. It has 6 dimensions including
physical functioning, role limitations, social functioning,
pain, mental health, and vitality [45].
The SG is a classic technique to obtain individual prefer-
ences for health outcomes, based on the theory of von
Neumann and Morgenstern [2]. In the study by Dion et.
al., the respondent was offered a choice between the cer-
tain outcome of a particular health state and a hypotheti-
cal gamble, with relative possibilities of perfect health and
immediate death varying. The gamble was terminated
when the respondent was indifferent to the choice
between the given health state and the gamble. The VAS
used by Dion et. al. was a 100 cm "feeling thermometer",
marked at each end by word descriptions as "immediate
death" and "perfect health". The respondents were asked
to put a mark at the point that represents their current
health status [23,24]. Similarly, a 10 cm length of hori-
zontal line (anchored at 0 cm = death and 10 cm = perfect
health) was used by Marra et. al. [25] as VAS.
Psychometric properties of HRQL instruments in 
tuberculosis
The SF-36 was used in 6 studies, and overall it showed
acceptable validity and reliability. Chamla [28] validated
the Chinese version SF-36 among active pulmonary TB
patients and the general population in China. The reliabil-
ity was tested by Cronbach's α, ranging form 0.88 to 0.97
for the eight SF-36 subscales. All 36 questions of the SF-36
had internal item consistency coefficients between 0.56
and 0.86. In Dion et. al. [23,24], the reliability of SF-36
was evaluated among a mixture of TB patients, including
25 with LTBI, 17 with active TB on treatment, and 8 with
previously treated TB. The internal consistency of the SF-
36 responses was strong, with coefficients of 0.86–0.92
for the two summary scores and 0.73–0.94 for the sub-
scale scores. The test-retest reliability (2-week interval) of
SF-36 was tested by calculating Intraclass Correlation
(ICC) coefficients: 0.66–0.79 for the two SF-36 summary
scores. He et. al. [33] also reported good reliability of the
Chinese version SF-36 (Cronbach' α > 0.7) among the two
groups of TB patients from China and Thailand.
Validity of the SF-36 was evaluated by examining the cor-
relations between SF-36 outcomes with other external var-
iables, including clinical criteria, responses from other
HRQL measures, and physician's evaluations. It was
reported that SF-36 scores were able to discriminate
between TB patients with different severity levels [21,26]
and between patients at different stages of treatment (i.e.,
the start, middle, and end of the treatment) [21,25,28]. In
Guo et. al. [26], the correlations between SF-36 summary
scores (PCS and MCS) and four utility instruments (SF-
6D, HUI-2, HUI-3, and VAS) were tested by calculating
Spearman's coefficients. SF-6D scores were strongly corre-
lated with both PCS and MCS (0.79, 0.80), and HUI-2,
HUI-3, and VAS scores were more strongly correlated with
PCS (0.59, 0.66, and 0.67) than with MCS (0.37, 0.48,
and 0.59). Similarly, in the study by Dion et. al. [23,24],
SF-36 scores were observed moderately correlated with
EQ-5D and VAS scores, but poorly correlated with SG
scores (Pearson coefficients < 0.2). Wang et. al. [27]
reported that patient-reported SF-36 scores were well cor-
related with physician proxy-reported Quality of Life
Index (QLI) and Karnofsky Performance Status (KPS)
scores, with correlation coefficients of 0.78 and 0.89
respectively. However, it was not reported which type of
correlation coefficient was calculated.Health and Quality of Life Outcomes 2009, 7:14 http://www.hqlo.com/content/7/1/14
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The structural validity of SF-36 was tested in two studies,
but the results were not consistent. In Chamala [28], fac-
tor analysis was applied to evaluate the 2-dimensional
model of the SF-36. Two factors (physical health and
mental health) were extracted and subjected to orthogo-
nal rotation using the Varimax method. The observed pat-
tern of correlations between the 8 subscales and the 2
factors supported the authors' prior hypothesis. For exam-
ple, it was reported that the 4 physical subscales (PF, RP,
BP, and GH) were correlated strongly with the physical
health factor, but only poorly correlated with the mental
health factor. On the other hand, the 4 mental subscales
(MH, RE, SF, and VT) were strongly correlated with the
mental health factor, but not the physical factor. He et. al.
[33] used principle component analysis to test the struc-
tural validity of SF-36. However, the results showed that
the 8 subscales were not well independent, and there were
overlapping items between different subscales. For exam-
ple, RE and RP subscales were both strongly correlated
among the two groups of patients (correlation coefficient
0.82 and 0.77). Based on their findings, the authors con-
cluded that the SF-36 did not show satisfactory construct
validity in the studied TB patients.
The application of SF-36 among TB patients also revealed
some problems. In the study by Dion et. al. [23,24], SF-36
subscales demonstrated a remarkable ceiling effect prob-
lem. Over 50% participants with concurrent or previous
TB reported the highest scores for 5 of SF-36 subscales (PF,
RP, RE, BP, and SF).
Ceiling and floor effects are a common problem for the
application of health utility instruments in TB. In Dion et.
al. [23,24], 42–53% participants reported the best possi-
ble EQ-5D health state. Guo et. al. also observed ceiling
and/or floor effect problems with three commonly used
health utility instruments. HUI-2 and HUI-3 suffered
from a serious ceiling effect problem, both in global score
and single dimension level. For example, 25% of active TB
patients scored 1.0 (perfect health) using the HUI-2 and
98% of them reported the best level of hearing for HUI-3.
SF-6D, on the other hand, was primarily limited by its nar-
row range of available utility values, from 0.30 to 1.0.
Health states at the lower end may not be adequately rep-
resented by the SF-6D. Despite these problems with the
application among TB patients, some positive aspects of
these utility instruments were also observed. For example,
these utility instruments showed moderate to strong cor-
relations with the SF-36 responses as stated before
[23,24,26]. Guo et. al. [26] also reported moderate to
strong agreement among SF-6D, HUI-2, HUI-3, and VAS,
using ICC: the overall ICC coefficient among these 4
instruments was 0.65 and paired ICC coefficients ranged
from 0.53 to 0.67. In addition, these four utility instru-
ments were all able to discriminate between TB patients
with different severity levels.
Pasipanodya et. al. [34] administered the lung disease-
specific SGRQ among people with treated pulmonary TB
disease or LTBI. Test-retest reliability of the SGRQ was
examined by ICC coefficients, 0.93 for the total score and
0.83–0.91 for subscale scores. Internal consistency was
tested by Cronbach's α, at 0.93. To evaluate its validity,
SGRQ responses were correlated with a previously vali-
dated MOS core questionnaire and a couple of clinical
pulmonary function tests, such as the forced vital capacity
(FVC). Overall, SGRQ scores and MOS scores agreed on
similar health constructs and diverged on dissimilar con-
structs. Low but significant correlations were observed
between SGRQ scores and pulmonary function test results
(-0.12 to -0.29, p < 0.05). On the other hand, a ceiling
effect problem for SGRQ was observed. In both treated
pulmonary TB patients and people with LTBI, the distri-
bution of SGRQ scores was skewed toward higher HRQL.
In addition, considering varied levels of reading and
understanding in English in respondents, different lan-
guage versions of SGRQ were used, but the potential
impact of combining results from these on HRQL out-
comes was not known.
Dhingra and Rajpal [21] applied the new TB-specific
instrument, DR-12, among TB patients under directly
observed therapy (DOT). It was reported that, at the
beginning of treatment, DR-12 scores demonstrated sig-
nificant differences between pulmonary and extra-pulmo-
nary TB patients, and between sputum positive and
sputum negative patients. Over the treatment period,
higher DR-12 score gains were observed among patients
who positively responded to the treatment compared to
those who did not. Based on these evidences, the authors
came to the conclusion that DR-12 had strong construct
validity in the studied population. However, the clinical
criteria or indicators were not well defined in the pub-
lished work. All comparisons were performed by using
paired or unpaired t-tests. Potential confounders such as
socio-demographic and clinical variables were not con-
trolled in the final data analysis.
Impact of tuberculosis on HRQL
Overall, active TB disease had significant and encompass-
ing impacts on patients' HRQL. Using the SF-36, Chamla
[28] found that, compared to the general population, peo-
ple with active TB disease scored significantly lower on PF,
RP, GH, BP, and VT (p < 0.05), but no significant differ-
ences were observed on RE, SF, and MH subscales (p >
0.05). In general, physical health subscales were more
affected than mental ones. Dion et. al. [23,24] also found
active TB patients scored significantly lower in SF-36 PCS
scores, but not in MCS scores, when compared to peopleHealth and Quality of Life Outcomes 2009, 7:14 http://www.hqlo.com/content/7/1/14
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with LTBI and those with previously treated TB disease. In
terms of health utility outcomes, Dion et. al. found that
active TB patients scored significantly lower in VAS
(median 92.5 VS. 97.5, p = 0.02) and SG (median 80.0 VS.
90.0, p = 0.002) than others at the baseline assessment.
However, no significant difference was observed in EQ-
5D scores between active TB patients and others. It is
likely that the small sample size and the heterogeneous
composition of subjects could have prevented the authors
from detecting the small but important differences in the
sample. Wang et. al. [27] found that active TB patients
reported lower scores (p < 0.01) across all SF-36 subscales
than healthy non-TB people, with RP and RE being most
affected. Marra et. al. and Guo et. al. [25,26] found that,
compared to those with LTBI, people with active TB scored
significantly lower at all SF-36 subscales, SF-6D, HUI-2,
HUI-3, and VAS. In contrast, SF-36 scores among people
with LTBI before the preventative therapy were very simi-
lar to the U.S. norm references.
In the study by Marra et. al. [25], Beck-DI scores showed
substantial impairment on mental well-being in active TB
patients, compared to people with LTBI. However, many
aspects of the Beck-DI (such as fatigue) can also be symp-
toms of TB and might not be necessarily indicative of
mental health impairments. Aydin and Ulusahin [31]
compared TB patients to COPD patients and found that
TB patients had a lower prevalence of depression and anx-
iety and a lower level of disability, suggested by GHQ-12
and BDQ scores. The authors postulated that the chronic
duration of COPD and the older age of the COPD patients
may result in a higher prevalence of psychological impair-
ments. Within TB patients, multi-drug resistant TB
patients reported the worst disability level, according to
BDQ outcomes. Yang et. al. [29] found that pulmonary TB
patients reported more psychological symptoms listed in
the SCL-90 and a lower degree of social support using
SSRS compared to healthy controls. However, SCL-90
scores did not show significant correlation with SSRS
scores, which is not consistent with the established rela-
tionship between social support and health [46], as dis-
cussed by the authors.
The impaired HRQL experienced by TB patients may be a
reflection of socio-demographic status (e.g., age, gender,
and socio-economic status) and other underlying co-mor-
bid conditions, besides TB and its treatment. A few
included studies explored the relationship between socio-
demographic features and clinical factors and HRQL in TB
patients. In general, the findings were consistent, but
some discrepancies existed. Yang et. al. [29] and
Nyamatihi et. al. [32] observed that females were more
likely to report poorer health than males, especially on
mental health problems, such as depression and anxiety.
Chamla [28] and Guo et. al. [26] found older people
tended to have poorer HRQL than younger ones. But
Duyan et. al. [30] did not find significant associations
between gender, age and HRQL in TB patients. On the
other hand, they [30] found that better HRQL was corre-
lated with higher income, higher education, better hous-
ing conditions, better social security, and closer
relationships with family members and friends. Some
clinical factors that were observed to correlate with poorer
HRQL in TB patients include size of pulmonary TB infec-
tion, duration of TB disease, reactivation of previous TB
infection, number of symptoms before treatment, devel-
opment of hemoptysis, hospitalization, underlying
chronic conditions, anemia, and count of white blood
cells before treatment [27,28].
Effect of anti-tuberculosis treatment on HRQL
Chamla [28], Dhingra and Rajpal [21], and Marra et. al.
[25] prospectively measured active TB patients' HRQL at
the start, middle, and end of treatment. In the study by
Chamla [28], after the anti-TB treatment, significant
improvement was observed in all physical health sub-
scales of the SF-36 (PF, RP, BP, and GH, p < 0.05); two
mental health subscales, RE and SF (p < 0.05), improved
significantly, but not VT and MH (p > 0.05). During the
treatment, RP, VT and MH scores decreased after the ini-
tial 2 months and but showed overall improvement at the
end of the treatment, while all other subscale scores
showed gradual increase over the treatment [28]. Dhingra
and Rajpal [21] observed a gradual improvement on DR-
12 scores in active TB patients over the course of the treat-
ment. Overall, a more identifiable improvement was
observed in symptom scores than that in socio-psycholog-
ical and exercise adaptation scores. Consistently, Marra et.
al. [25] also found significant HRQL improvement in
active TB patients over the 6 months of treatment, using
SF-36 and Beck-DI.
Although anti-TB treatment improved HRQL overall,
active TB patients still had poorer HRQL at the end of the
treatment compared to the general population or people
with LTBI, especially in psychological well-being and
social functioning. Chamla [28] observed that, at the end
of the treatment, active TB patients still scored signifi-
cantly lower at RP, VT, and MH subscales compared to
general population comparisons. Marra et. al. [25] found
that, after the 6 month of treatment, active TB patients
scored significantly lower at SF-36 PCS and MCS sum-
mary scores compared to people with LTBI. An interesting
finding by Marra et. al. [25] is that, after the preventive
treatment, MCS scores among people with LTBI decreased
significantly, while PCS scores remained unchanged. Pasi-
panodya et. al. [34] measured HRQL among pulmonary
TB patients who completed at least 20 weeks of treatment,
using the SGRQ. Compared with those with LTBI, treated
TB patients had lower SGRQ scores. Those with betterHealth and Quality of Life Outcomes 2009, 7:14 http://www.hqlo.com/content/7/1/14
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lung functions and/or born in the U.S. (against foreign-
born) tended to have better HRQL outcomes. No gender
difference was observed in SGRQ scores.
Muniyandi et. al. [35] assessed the HRQL in a sample of
previous TB patients one year after successful completion
of treatment. 40% of these people reported persistent
symptoms, such as breathlessness, cough, chest pain, and
occasional fever. The authors calculated three SF-36 com-
ponent scores: the physical well-being, mental well-being,
and social well-being. Based on their results, there was no
gender difference on physical well-being score; but
females scored much lower at mental and social well-
being scores. Compared with younger people, older ones
had significantly lower physical and mental well-being
scores, but not the social score. They also presented the
U.S. general population norms for the three component
scores and concluded that TB patients' HRQL returned to
normal level one year after the completion of treatment.
However, the way of calculating the three SF-36 compo-
nent scores is not commonly seen in literatures, and the
reference regarding the U.S. general population norms
provided in the published paper cannot be located.
Discussion
HRQL has been appreciated as an important health out-
come measure in clinical research. We identified 12 origi-
nal studies where multi-dimensional HRQL was assessed
among people with TB disease or infection using struc-
tured instruments around the world. We found that TB
and its treatment have a significant impact on patients'
quality of life from various aspects and this impact tends
to persist for a long time even after the successful comple-
tion of treatment and the microbiological 'cure' of the dis-
ease.
The results suggest that TB disease has a negative and
encompassing impact on active TB patients' self-perceived
health status in physical, psychological, and social
aspects. Overall, the anti-TB treatment showed positive
effect on improving patients' HRQL. It appeared that
physical health seemed to be more affected by the disease
but improved more quickly after the treatment, while the
impairment on mental well-being tended to persist for a
longer term [21,28]. However, even after the active TB
patients successfully completed the treatment and were
considered microbiologically 'cured', their HRQL
remained poor as compared to the general population
[23-25,28]. The ongoing HRQL impairment may be partly
due to the persistent physical symptoms and residual
physiological damages from the disease and/or the treat-
ment. Furthermore, a few qualitative studies [9-14,16-18]
have shown that the social stigma attached to the diagno-
sis of TB in some cultures is significant. People with TB
may feel isolated from their family and friends or experi-
ence the fear and anxiety of being known by others about
their diagnosis. All these consequential impairments also
need to be 'cured' and may take a long recovery time.
Most studies have focused on assessing HRQL in active TB
patients. Although people with LTBI do not present with
clinical disease or symptoms, they are likely to be sub-
jected to the same social and psychological impacts as
active TB patients. The knowledge of a deadly and stigma-
tized disease lying dormant in his/her body may also
induce anxiety and fear. As Marra et. al. [25] observed
that, after receiving 6 months of preventive therapy with
isoniazid, the mental well-being of people with LTBI
decreased significantly.
HRQL assessment in TB research is still a new area, and a
valid and reliable TB-specific instrument is much needed.
Currently, a wide range of HRQL instruments were uti-
lized in the literature. The SF-36 was the most frequently
used instrument and it appeared to be a valid and reliable
tool to be used in TB. Although the SF-36 has been used
extensively to assess both population health and specific
health conditions for various medical conditions, as a
generic health assessment instrument, it offers little infor-
mation to help understand the unique experiences among
TB patients, such as social stigma and anti-TB treatment
related ADRs.
Our review identified one TB-specific HRQL instrument,
DR-12, which was developed in India [20,21]. Unfortu-
nately, its validation study was not conducted in a system-
atic fashion and the current evidence provided was not
convincing. Further applications and appropriate meth-
odologies are needed to show DR-12 is a psychometrically
sound HRQL instrument feasible and valid for TB
patients. In addition, the DR-12 is actually designed spe-
cifically for pulmonary TB patients, judging from its item
content. TB can affect almost any part of the human body,
and in Canada, about 40% of active TB diseases would
present as extra-pulmonary TB [47]. Different types of TB
disease would have very different clinical presentations
and affect people's function differently. This may be a
challenge when developing a TB-specific HRQL instru-
ment.
It should be also noted that most TB patients have very
different cultural and socio-demographic backgrounds
compared with the population in which many of these
instruments were originally developed. Also, in the stud-
ies done in Canada and the USA [24-26,32,34], most TB
patients were foreign-born and the instruments were nor-
mally self-administered in the English language which
would not have been the respondents' first language.
Thus, the results of these studies may not be valid if care-
ful translation and cultural adaptation of the instrumentHealth and Quality of Life Outcomes 2009, 7:14 http://www.hqlo.com/content/7/1/14
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was not done to accommodate the multi-cultural popula-
tion.
Particular attention should be given to some methodolog-
ical issues on assessing HRQL among people with active
TB disease or LTBI. To comprehensively examine the
impact of TB and its treatment on patients' HRQL, it is
very important to include a proper comparison group
from a similar demographic and socio-economic back-
ground. When conducting the study, researchers are rec-
ommended to seek statistical consultation regarding
proper sample size estimating, missing data handling, and
adjusting for potential confounders, such as socio-demo-
graphic status and presence of co-morbidities. Another
concern is the lack of interpretation of HRQL outcomes in
terms of clinical meaningfulness. Statistical significance is
a useful way to interpret the result, but it fails to relate the
HRQL outcome with clinical relevance. As such, more
work needs to be done to relate changes in HRQL assess-
ment in TB to concepts such as the minimal clinical differ-
ence [48,49].
Conclusion
Our review of the literature shows that TB diminishes
patients' HRQL, as measured by various instruments.
However, due to the heterogeneity of HRQL measure-
ments, it was difficult to assimilate results across studies.
A few studies used the SF-36 which appeared to be a valid
instrument in the measurement of HRQL in TB. Other
instruments require further psychometric testing to deter-
mine their suitability in measurement in this context. Our
review suggests that HRQL assessment in people with TB
is a growing research area and a psychometrically sound
TB-specific HRQL instrument is lacking. A critical step in
the future would be to design an applicable, reliable, and
valid TB-specific HRQL instrument. Particular attention
should be given to address the methodological issues
when conducting a HRQL assessment study in TB
patients.
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